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Background: Afatinib is an irreversible second-generation epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitor (TKI) while gefitinib or erlotinib are reversi-
ble first-generation EGFR-TKIs.
Methods: A retrospective analysis of patients with EGFR mutant advanced lung adeno-
carcinoma receiving first-line afatinib versus gefitinib or erlotinib at University Malaya
Medical Centre from 1st January 2015 to 31th December 2018.
Results: Of 113 patients, 24 (21.2%) received afatinib, 63 (55.8%) received gefitinib
and 26 (23.0%) received erlotinib in first-line setting. Their demographic and clinical
characteristics are shown in the table. Afatinib was used significantly more frequently
in patients with rare or complex EGFR mutations (p¼ 0.005), and more often in
patients with symptomatic brain metastases. The median progression-free survival
(mPFS) of patients treated with afatinib (13.1 months) was longer than that of patients
treated with gefitinib (10.9 months) or erlotinib (7.8 months) (p¼ 0.479). Patients
receiving afatinib had consistently longer PFS than patients receiving gefitinib for the
first 17 months and erlotinib for the first 20 months. The overall response rate was
higher in patients on afatinib (75.0%) than those on gefitinib (63.5%) or erlotinib
(53.8%). There was no difference in the disease control rate. Three patients (2.7%) had
severe side-effects while on EGFR-TKI. Of two patients on afatinib, one had grade-3
diarrhea while another had grade 3 stomatitis, rash and paronychia. One patient had
grade 3 rash on gefitinib.
Conclusions: Patients receiving first-line afatinib demonstrated longer mPFS than
those on first-line gefitinib or erlotinib. The lack of statistical significance in this study
is because of the small number of patients treated with afatinib, more frequent rare or
complex EGFR mutations and more symptomatic brain metastases among afatinib
treated patients.
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Table: 487P Clinical characteristic of 113 patients on first-line EGFR-TKI
Characteristics, No (%) Afatinib (24) Gefitinib (63) Erlotinib (26) p-value
Symp brain mets No Yes 17 (70.8) 7 (29.2) 53 (84.1) 10 (15.9) 22 (84.6) 4 (15.4) 0.181
EGFR subtype 19 del 21 L858R Rare/complex 16 (66.7) 2 (8.3) 6 (25.0) 39 (61.9) 20 (31.7) 4 (6.3) 22 (84.6) 3 (11.5) 1 (3.8) 0.005
Side-effect grade 1-2 grade 3 22 (91.7) 2 (8.3) 62 (98.4) 1 (1.6) 26 (100) 0 0.007
Objective response Yes No 18 (75.0) 6 (25.0) 40 (63.5) 23 (36.5) 14 (53.8) 12 (46.2) 0.298
Disease control Yes No 23 (95.8) 1 (4.2) 59 (93.7) 4 (6.3) 24 (92.3) 2 (7.7) 0.872
Median PFS Months Event, No. (%) 13.1 19 (79.2) 10.9 49 (77.8) 7.8 19 (73.1) 0.479
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